<DOC>
	<DOCNO>NCT00028756</DOCNO>
	<brief_summary>Randomized phase III trial compare effectiveness immediate adjuvant chemotherapy adjuvant chemotherapy give cancer return treat patient undergone radical cystectomy stage III stage IV transitional cell carcinoma bladder urothelium . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug give surgery may kill remain tumor cell . It yet know adjuvant chemotherapy effective give immediately radical cystectomy ( surgery remove bladder ) cancer return .</brief_summary>
	<brief_title>Comparison Immediate Delayed Adjuvant Chemotherapy Treating Patients Who Have Undergone Radical Cystectomy Stage III Stage IV Transitional Cell Carcinoma Bladder Urothelium</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Compare overall progression-free survival patient stage III IV transitional cell carcinoma bladder urothelium treat immediate versus defer adjuvant chemotherapy radical cystectomy . OUTLINE : This randomize , multicenter study . Patients stratify accord participate center , tumor status ( pT1-2 v pT3 v pT4 ) , node status ( node positive v node negative 15 node sample vs node negative less 15 node sample ) . Patients randomize one two treatment arm . ARM I : Beginning within 90 day radical cystectomy , patient receive total 4 course adjuvant chemotherapy . ARM II : Beginning time clinical relapse , patient receive total 6 course adjuvant chemotherapy . Patients arm receive one follow chemotherapy regimen determine participate center : REGIMEN A ( Classical M-VAC ) : Patients receive classical M-VAC comprising methotrexate IV day 1 , 15 22 ; vinblastine IV day 2 , 15 , 22 ; doxorubicin IV cisplatin IV day 2 . Courses repeat every 28 day . REGIMEN B ( High-dose M-VAC ) : Patients receive high-dose M-VAC comprising methotrexate IV day 1 vinblastine IV , doxorubicin IV , cisplatin IV day 2 . Patients also receive filgrastim ( G-CSF subcutaneously daily day 4-10 . Courses repeat every 14 day . REGIMEN C ( Gemcitabine cisplatin ) : Patients receive gemcitabine IV 30 minute day 1 , 8 , 15 follow cisplatin IV day 1 2 . Courses repeat every 28 day . Patients follow every 3 month 1 year , every 6 month 5 year , annually thereafter . Peer Reviewed Funded Endorsed Cancer Research UK EORTC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Histologically confirm transitional cell carcinoma bladder urothelium T34 , N13 , M0 No pure squamous cell adenocarcinoma tumors No 90 day since prior radical cystectomy bilateral lymphadenectomy without evidence microscopic residual disease Performance status WHO 01 WBC least 3,500/mm^3 Platelet count least 120,000/mm^3 SGOT/SGPT less 2.5 time upper limit normal ( ULN ) Alkaline phosphatase less 2.5 time ULN Bilirubin normal Glomerular filtration rate great 60 mL/min No clinically significant cardiac arrhythmia No congestive heart failure No complete bundle branch block No New York Heart Association class III IV heart disease Not pregnant nursing Fertile patient must use effective contraception 6 month study Considered fit cisplatincontaining combination chemotherapy No clinically abnormal auditory function No known hypersensitivity E. coliderived drug preparation No grade 2 great peripheral neuropathy No prior concurrent malignancy except adequately treat carcinoma situ cervix , treat basal cell skin cancer , treat incidental prostate cancer ( pT2 , Gleason score great 6 , PSA le 0.5 ng/mL ) No psychological , familial , sociological , geographical condition would preclude study involvement No prior systemic chemotherapy No prior radiotherapy bladder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>